Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more
Market Cap & Net Worth: Bio-Gene Technology Ltd (BGT)
Bio-Gene Technology Ltd (AU:BGT) has a market capitalization of $6.61 Million (AU$10.68 Million) as of March 19, 2026. Listed on the AU stock exchange, this Australia-based company holds position #33812 globally and #1196 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bio-Gene Technology Ltd's stock price AU$0.04 by its total outstanding shares 305061108 (305.06 Million).
Bio-Gene Technology Ltd Market Cap History: 2017 to 2026
Bio-Gene Technology Ltd's market capitalization history from 2017 to 2026. Data shows change from $36.83 Million to $6.61 Million (-18.94% CAGR).
Bio-Gene Technology Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bio-Gene Technology Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.22x
Bio-Gene Technology Ltd's market cap is 10.22 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $36.83 Million | $6.32K | -$1.05 Million | 5831.78x | N/A |
| 2018 | $18.89 Million | $344.45K | -$2.83 Million | 54.84x | N/A |
| 2019 | $37.78 Million | $508.76K | -$1.92 Million | 74.26x | N/A |
| 2020 | $26.44 Million | $907.58K | -$1.93 Million | 29.14x | N/A |
| 2021 | $38.72 Million | $62.61K | -$2.40 Million | 618.47x | N/A |
| 2022 | $18.89 Million | $445.73K | -$2.91 Million | 42.38x | N/A |
| 2023 | $11.33 Million | $149.23K | -$3.10 Million | 75.94x | N/A |
| 2024 | $8.12 Million | $18.32K | -$2.41 Million | 443.36x | N/A |
| 2025 | $4.34 Million | $425.07K | -$2.58 Million | 10.22x | N/A |
Competitor Companies of BGT by Market Capitalization
Companies near Bio-Gene Technology Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Bio-Gene Technology Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bio-Gene Technology Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Bio-Gene Technology Ltd's market cap moved from $36.83 Million to $ 6.61 Million, with a yearly change of -18.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$6.61 Million | +52.17% |
| 2025 | AU$4.34 Million | -46.51% |
| 2024 | AU$8.12 Million | -28.33% |
| 2023 | AU$11.33 Million | -40.00% |
| 2022 | AU$18.89 Million | -51.22% |
| 2021 | AU$38.72 Million | +46.43% |
| 2020 | AU$26.44 Million | -30.00% |
| 2019 | AU$37.78 Million | +100.00% |
| 2018 | AU$18.89 Million | -48.72% |
| 2017 | AU$36.83 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bio-Gene Technology Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.61 Million USD |
| MoneyControl | $6.61 Million USD |
| MarketWatch | $6.61 Million USD |
| marketcap.company | $6.61 Million USD |
| Reuters | $6.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.